Strategies to Demonstrate the Value of Pharmacists\u27 Cognitive Services by Drabinski, Amy
Health Policy Newsletter
____________________________________________________________ 
Volume 13 Number 4    December, 2000               Article 11 
____________________________________________________________ 
 
Strategies to Demonstrate the Value of 
Pharmacists’ Cognitive Services 
 
Amy Drabinski, PharmD, MBA* 
 
* Knoll Pharmaceuticals
Copyright ©2000 by the author.  Health Policy Newsletter is a quarterly publication of TJU, JHS 
and the Office of Health Policy and Clinical Outcomes, 1015 Walnut Street, Suite 115, 
Philadelphia, PA 19107.
Suggested Citation:
Drabinski A.  Strategies to demonstrate the value of pharmacists’ cognitive services.  Health 
Policy Newsletter 2000; 13(4): Article 11.  Retrieved [date] from 
http://jdc.jefferson.edu/hpn/vol13/iss4/11.
Amy Drabinski:  Value of Pharmacists’ Cognitive Services
Health Policy Newsletter  Vol. 13, Number 4 (December 2000), Article 11
Strategies to Demonstrate the Value of Pharmacists’ 
Cognitive Services  
__________________________________________ 
 
Health Partners, which is a managed care plan in Philadelphia, and the Office of 
Health Policy and Clinical Outcomes (OHP), participated in a continuing education 
program for pharmacists at Temple University. The purpose of this program was to 
educate pharmacists about how to measure the effect of cognitive services that they 
provide to asthmatics so that fees for these services can be established. Cognitive 
services include counseling patients, profiling medications, and performing any 
function other than dispensing medicines. Michael Schaffer, PharmD, MBA, Director 
of Health Policy and Clinical Outcomes at Health Partners (and a former fellow of the 
OHP), and Amy Drabinski, PharmD, MBA, a current health outcomes research fellow 
at Knoll Pharmaceuticals, presented outcomes research as it applies to asthma. They 
focused on the importance of the pharmacist’s role in measuring and documenting 
asthma-related outcomes.  
 
Dr. Schaffer introduced the concept of Economic, Clinical and Humanistic Outcomes 
(ECHO), which proves useful in helping pharmacists to justify cognitive services. 
Economic outcomes involve both direct medical costs of treating the disease (costs of 
physician visits, prescriptions, emergency room visits) and indirect medical costs 
(transportation and lost productivity). Clinical outcomes are medical events that 
occur as result of a disease and include symptoms and hospitalizations. Humanistic 
outcomes measure a patient’s functional status or quality of life (QOL). The ECHO 
model recognizes the importance of systematically collecting outcomes data to 
determine the value of the effectiveness and consequences of treatment 
alternatives.1
Asthma is costly to the American healthcare system.2 Pharmacists can have a 
positive impact on quality of life and cost of treatment for asthmatics by participating 
in disease management programs and through one-on-one counseling. Although 
pharmacists spend a significant amount of time providing cognitive services to 
asthmatics, they encounter obstacles in justifying reimbursement for these services. 
Pharmacists often struggle with quantifying the impact that counseling patients and 
profiling their medications has on a patient’s condition. To justify reimbursement for 
cognitive services, pharmacists need to learn how to measure the difference that 
their actions make on patients with asthma. They can do this by looking at the 
influence that intervention and counseling have on economic, clinical, and humanistic 
(QOL) outcomes.   
 
Humanistic outcomes are difficult to measure. Dr. Drabinski discussed methods of 
measuring them through two common types of questionnaires. Both questionnaires 
measure QOL, although one is generic, and one is disease-specific.   
 
The two generic instruments that are used most often are the SF-36 and the 
Sickness Index Profile (SIP). Measuring QOL with generic questionnaires allows 
comparisons to be made between patients across all different disease states.3
However, these instruments may not capture changes relevant to asthmatics and 
tend not to be very sensitive to small changes3. The limitations of generic 
questionnaires have led researchers to develop disease-specific surveys. These focus 
on conditions that are specific to asthmatics, such as the degree of breathlessness 
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and other symptoms related to asthma. The standard asthma-specific QOL 
questionnaires are the Asthma Quality of Life Questionnaire (AQLQ)3 and the Living 
with Asthma Questionnaire (LWAQ).3 Both reflect small changes in asthmatics’ 
QOL.3
Interpretation limits the validity of all QOL questionnaires.  One way to determine 
the clinical significance of scores is to assess the minimal important difference - the 
smallest difference in score improvement which patients perceive as beneficial and 
which would mandate a change in the patient’s management.4
To promote reimbursement for cognitive services, pharmacists need to measure and 
quantify their impact on QOL in conjunction with other clinical and economic 
outcomes. When selecting a QOL instrument, consider the strengths and weaknesses 
of each questionnaire, including its ability to detect change. Patients and their 
insurance companies will be looking for measurable proof that cognitive services 
have a direct positive effect on the condition of patients with asthma. 
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